ForGrowth NAP B.V.
CIK: 0002005407
Associated companies
Transaction History
| NAMS | ▼ Sell | Open Market | 29,846 | $762K | 12/30/2024 | View on chart |
| NAMS | ▼ Sell | Open Market | 41,472 | $1.1M | 12/27/2024 | View on chart |
| NAMS | ▼ Sell | Open Market | 33,438 | $870K | 12/26/2024 | View on chart |
| NAMS | ▼ Sell | Open Market | 16,164 | $415K | 12/24/2024 | View on chart |
| NAMS | ▼ Sell | Open Market | 25,132 | $641K | 12/23/2024 | View on chart |
| NAMS | ▼ Sell | Open Market | 5,629 | $147K | 12/20/2024 | View on chart |
| NAMS | ▼ Sell | Open Market | 44,143 | $1.1M | 12/20/2024 | View on chart |
| NAMS | ▼ Sell | Open Market | 56,506 | $1.4M | 12/19/2024 | View on chart |
| NAMS | ▼ Sell | Open Market | 46,210 | $1.2M | 12/18/2024 | View on chart |
| NAMS | ▼ Sell | Open Market | 54,518 | $1.4M | 12/18/2024 | View on chart |
| NAMS | ▼ Sell | Open Market | 66,648 | $1.7M | 12/17/2024 | View on chart |
| NAMS | ▼ Sell | Open Market | 47,736 | $1.3M | 12/17/2024 | View on chart |
| NAMS | ▼ Sell | Open Market | 1,096 | $27K | 12/16/2024 | View on chart |
| NAMS | ▼ Sell | Open Market | 25,751 | $644K | 12/13/2024 | View on chart |
| NAMS | ▼ Sell | Open Market | 140,048 | $3.5M | 12/12/2024 | View on chart |
| NAMS | ▼ Sell | Open Market | 25,963 | $680K | 12/12/2024 | View on chart |
| NAMS | ▼ Sell | Open Market | 130,561 | $3.3M | 12/11/2024 | View on chart |
| NAMS | ▼ Sell | Open Market | 4,894 | $133K | 12/11/2024 | View on chart |
| NAMS | ▼ Sell | Open Market | 18,583 | $491K | 12/11/2024 | View on chart |
| NAMS | ▼ Sell | Open Market | 259,739 | $6.6M | 12/10/2024 | View on chart |
| NAMS | ▼ Sell | Open Market | 48,511 | $1.3M | 12/10/2024 | View on chart |
| NAMS | ▼ Sell | Open Market | 33,273 | $834K | 11/18/2024 | View on chart |
| NAMS | ▼ Sell | Open Market | 8,530 | $213K | 11/15/2024 | View on chart |
| NAMS | ▼ Sell | Open Market | 9,832 | $246K | 11/14/2024 | View on chart |
| NAMS | ▼ Sell | Open Market | 1,066 | $27K | 11/13/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
RBC Capital Lowers Target to $42 for NAMS
RBC Capital has kept its outperform rating for NewAmsterdam Pharma (NAMS) but cut its price target to $42. The new target sits at the top of the 52‑week range and near the current support level of $35.04. The stock’s RSI of 33.5 suggests it is in an oversold zone, which may influence short‑term trading activity. Analysts still see upside potential, but the lowered target reflects a more cautious outlook.
RBC Capital Lowers Target to $42 for NAMS. RBC Capital has kept its outperform rating for NewAmsterdam Pharma (NAMS) but cut its price target to $42. The new target sits at the top of the 52‑week range and near the current support level of $35.04. The stock’s RSI of 33.5 suggests it is in an oversold zone, which may influence short‑term trading activity. Analysts still see upside potential, but the lowered target reflects a more cautious outlook.